Printer Friendly

Gestational diabetes mellitus.

Gestational diabetes mellitus (GDM) [3] is defined as diabetes diagnosed during pregnancy that is not clearly overt diabetes (1). This condition is associated with adverse pregnancy outcomes, including fetal macrosomia, stillbirth, neonatal metabolic disturbances, and related problems (2). Offspring of mothers with GDM are at increased risk for diabetes and obesity (3-5). Women with GDM are more likely to develop diabetes in the years following pregnancy (4, 6). There continues to be controversy regarding the degree of risk associated with GDM, the most appropriate diagnostic criteria, the ability of identification and treatment to improve pregnancy outcomes, and the cost vs benefit of such efforts.


As early as 1882, J. Matthews Duncan observed that diabetes might appear during pregnancy and cease with the end of pregnancy (7). In the 1950s, W.P.U. Jackson reported a high likelihood of previous stillbirth and fetal macrosomia in women with diabetes (8), and in 1957 Elsie Reed Carrington et al. coined the term "gestational diabetes" (9). In the US at that time, the diagnosis of diabetes was made with a 100-g, 3-h oral glucose tolerance test (OGTT) using the US Public Health Service Criteria. In 1964 O'Sullivan and Mahan (10) noted that the OGTT maybe altered by pregnancy and reported on the results of 100-g, 3-h OGTTs in 752 pregnant women, most of whom were tested in the second and third trimesters. Potential cutoffs were 1, 2, and 3 SDs above the mean for each of the 4 values. These cutoffs were then retrospectively applied to a second data set of OGTTs in 1013 previous pregnancies in women who subsequently underwent periodic OGTTs in the nonpregnant state. Two or more increased glucose values, rather than a single abnormality, were used as diagnostic criteria to avoid reliance on a single laboratory measurement to make a diagnosis. This pioneering work revealed that the use of 2 SDs above mean values would result in a 1.99% prevalence of gestational diabetes, which was similar to the reported prevalence of diabetes in the nonpregnant population at the time. Furthermore, diabetes would develop in 22.6% of individuals formerly diagnosed with GDM within the ensuing 8 years. The "O'Sullivan" thresholds, both the raw numbers and the easier-to-remember rounded numbers, depicted in Table 1, came into widespread use by the 1970s. These thresholds were based on venous whole blood samples analyzed by the SomogyiNelson technique. Because most laboratories had switched to plasma or serum measurements, the National Diabetes Data Group (NDDG) proposed newly derived thresholds in 1979 (11). The already rounded O'Sullivan values were increased by approximately 15% to account for the difference between whole blood glucose and plasma or serum glucose. In 1982 we published a second set of thresholds derived from the O'Sullivan and Mahan raw numbers, but decreased by 5 mg/dL (0.28 mmol/L) because of the universal change in laboratory methods from those used for the Somogyi-Nelson method, which measured approximately 5 mg/dL of reducing substances other than glucose, to more specific enzymatic methods (12). The resulting values were then increased by 14% to account for the change from whole blood to plasma. The 2 sets of thresholds, both derived from the O'Sullivan and Mahan criteria, are generally referred to as "NDDG" and "Carpenter and Coustan" (C&C) criteria. Both were deemed acceptable by the American College of Obstetricians and Gynecologists (ACOG) and are still recommended as reasonable alternatives (13). A head-to-head comparison of the 2 sets of criteria, performed by using the original methodology of O'Sullivan and Mahan vs plasma and glucose oxidase, found that the C&C criteria were within 95% confidence limits of the original values, whereas the NDDG were above the 95% confidence limits at each of the 3 postload times of measurement (14). The American Diabetes Association (ADA) subsequently endorsed the C&C criteria, and these remained their recommended diagnostic thresholds until 2011, when a new set of diagnostic criteria was incorporated into the ADA's recommendations (1).

Because the O'Sullivan criteria, and the thresholds which were derived from them, were validated solely on their ability to predict subsequent diabetes in the mother, it became clear that evidence-based criteria, validated by their prediction of adverse pregnancy outcomes, would be preferable. Furthermore, other diagnostic tests are being used in various parts of the world (15). These include the WHO criteria, which are based on a 75-g, 2-h OGTT with thresholds the same for women during pregnancy as for nonpregnant individ uals (16). Gestational diabetes is diagnosed using the nonpregnant criteria for impaired glucose tolerance, a fasting value <126 mg/dL (6.99 mmol/L) plus a 2-h value of 140-199 mg/dL (8.27-11.05 mmol/L). A fasting plasma glucose [greater than or equal to] 126 mg/dL or a 2-h value [greater than or equal to] 200 mg/dL ([greater than or equal to] 11.1 mmol/L) is diagnostic for diabetes. The use of different sets of criteria and different glucose loads around the world make it impossible to compare the prevalences of GDM and the results of treatment among various locations. Published prevalence figures vary from 1.7% to 11.7% in countries throughout the world (17), and from 3.4% to 7.2% even among states in the US (18). The 75-g, 2-h OGTT has been accepted for use around the world in nonpregnant individuals, but different glucose challenges used in pregnancy in various centers (e.g., 50, 75, or 100 g) make it nearly impossible to compare studies and results to one another.

For the above reasons the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study was designed to evaluate the relationship between plasma glucose concentrations on the 75-g, 2-h OGTT and various adverse pregnancy outcomes (19). It was hoped that this would inform the development of evidence-based diagnostic criteria, which might then be widely adapted. Blinded OGTTs were administered to over 23 000 pregnant women in the late second and early third trimester in 14 centers in 9 countries around the world. The primary outcomes of macrosomia (birth weight >90th centile), fetal hyperinsulinemia (cord C-peptide >90th centile), clinical neonatal hypoglycemia, and primary cesarean section were all related to each of the 3 plasma glucose measurements (fasting, 1 h, and 2 h) in a continuous fashion, down to the lowest concentrations of glucose, with no inflection points (Fig. 1). Secondary outcomes such as preeclampsia, neonatal body fat (skin-fold thickness), neonatal intensive care unit (NICU) admission, and preterm birth were similarly related. These findings of a direct relationship between GTT values at 24-32 weeks gestation and ultimate out comes support the Pedersen hypothesis (20) of maternal hyperglycemia causing fetal hyperinsulinemia leading to increased fetal fat deposition and macrosomia. Although the HAPO study did not address the relationship of fasting values [greater than or equal to] 105 mg/dL ([greater than or equal to] 5.83 mmol/L) or 2-h values [greater than or equal to] 200 mg/dL ([greater than or equal to] 11.1 mmol/L) with adverse pregnancy outcomes, numerous other reported studies have demonstrated such an association. The fact that the relationship holds down to the lowest glucose concentrations suggests a basic biologic phenomenon.


Given the lack of an inflection point for any of these relationships, there were no obvious diagnostic cutoffs. The selection of diagnostic criteria would, of necessity, be somewhat arbitrary. The International Association of Diabetes In Pregnancy Study Groups (IADPSG) was called upon to oversee a process in which data were presented to, and input solicited from, a broad range of experts and constituencies from throughout the world (21). Consideration was given to the use of OGTT cutoffs that identified odds ratios of 1.5, 1.75, or 2.0 (compared to median values) for the risk of fetal macrosomia, neonatal adiposity, and fetal hyperinsulinemia (all defined as >90th percentile). Although it would have been desirable to use a single glucose value rather than performing a full OGTT, it was determined that the 3 values of the OGTT each contributed independently to the prediction of adverse outcomes. Consequently the IADPSG recommended the use of the 75-g, 2-h OGTT with cutoffs at an odds ratio of 1.75, as depicted in Table 2. Because much of the world uses the International System of Units (mmol/L), whereas the US employs milligrams per deciliter, the unrounded values were recommended. In addition, rounding up or down to the nearest 5 mg/dL (or 0.5 mmol/L) would have significantly impacted the prevalence of diagnosed GDM.

The IADPSG recommendations, when applied to the HAPO data, would have identified 16.1% of pregnant women as having GDM, and that figure increased to approximately 18% when women who were ex cluded from the study because of high glucose values were considered (21). This recommendation has been controversial, and arguments for and against can be found in a previous issue of this journal (22, 23). Such a high prevalence of GDM has major implications for healthcare delivery. However, the recommended thresholds for GDM are not dissimilar to the current generally accepted diagnostic criteria for prediabetes (Table 3) in nonpregnant individuals. In view of the current 11.3% prevalence of diabetes in the US adult population (24) and the 35% prevalence of prediabetes (25), the proposed increase in prevalence of GDM does not seem unreasonable. The ADA has endorsed the IADPSG recommendations (1) for diagnosing gesta tional diabetes, whereas ACOG has not done so as yet (13).

The IADPSG made further recommendations to enable detection of preexisting diabetes during early pregnancy (21). A fasting plasma glucose [greater than or equal to] 126 mg/dL (6.99 mmol/L), random plasma glucose [greater than or equal to] 200 mg/dL (11.1 mmol/L), or hemoglobin [A.sub.1c] ([HbA.sub.1c]) [greater than or equal to] 6.5% ([greater than or equal to] 48 mmol/mol) would be the basis for making the diagnosis (Table 2). The ADA has endorsed a similar recommendation (1), although requiring a second, confirmatory test. The ADA permits defining overt diabetes with a random glucose [greater than or equal to] 200 mg/dL only for patients who exhibit classic symptoms of hyperglycemia or hyperglycemic crisis. In contrast, a random glucose of [greater than or equal to] 200 mg/dL may be used in the presence or absence of such symptoms, but it must be confirmed by an [HbA.sub.1c] or fasting plasma glucose, according to the IADPSG. The IADPSG suggests either testing all pregnant women, or testing only those with risk factors, at the first prenatal visit, whereas the ADA recommends testing only those with risk factors. Both organizations recommend the 75-g, 2-h OGTT for GDM at 24-28 weeks in those who have not already been diagnosed with diabetes or GDM.

Screening and Testing Strategies

The ACOG recommends universal screening as the most sensitive approach, but there may be pregnant women at low risk who are less likely to benefit from testing. To be considered low risk, women must be younger than 25 years, not be a member of a racial or ethnic group with a high prevalence of diabetes, not be overweight, have no history of abnormal glucose tolerance or adverse pregnancy outcomes, and have no known diabetes in a first-degree relative. The first step in screening for gestational diabetes is a 50-g, 1-h glucose challenge (13) at 24-28 weeks. Values [greater than or equal to] 130 mg/dL ([greater than or equal to] 7.22 mmol/L) or [less than or equal to] 140 mg/dL ([greater than or equal to] 7.77 mmol/L) are followed up with a 100-g, 3-h OGTT. Two or more increased values are diagnostic for GDM. Either the NDDG or C&C modifications are acceptable (Table 1). The new recommendation from the ADA (1) for diagnosing gestational diabetes is the 75-g, 2-h OGTT, which is not a screening test but rather a diagnostic test.

Implications of Gestational Diabetes

Maternal hyperglycemia, whether from preexisting diabetes or from gestational diabetes, leads to fetal hyperglycemia because glucose is easily transferred across the placenta. The fetal pancreas responds to increased glucose concentrations by producing and releasing more insulin. It is this fetal hyperinsulinemia that leads to most of the fetal problems, collectively known as diabetic fetopathy, seen in diabetic pregnancy (26). Fetal macrosomia is one of the more prominent problems and appears to be related to the growth-promoting activity of fetal insulin. The excessive growth is disproportional and leads to large amounts of subcutaneous fat and broad shoulders, which predispose infants to shoulder dystocia at delivery. Infants of gestational diabetic mothers who are born prematurely are more likely to develop respiratory distress syndrome and other problems of prematurity. Hyperinsulinemic babies are prone to hypoglycemia during the early neonatal period, when they are suddenly isolated from the maternal source of glucose and still have high concentrations of circulating insulin. Other problems encountered by such infants include hypocalcemia, hyperbilirubinemia, and plethora. Such problems may require close monitoring in the NICU. Offspring of gestational diabetic mothers have an increased risk of developing both obesity and diabetes later in life (3-5).

Gestational diabetes also has implications for the mother. Preeclampsia and cesarean sections are both increased in undiagnosed, untreated GDM and maybe prevented with diagnosis and treatment (27, 28). Although gestational diabetes is not, of itself, an indication for cesarean section, its complications maybe. For example, preeclampsia may necessitate early delivery by induction of labor before the cervix is "ripe," making cesarean section more likely. When the estimate of fetal weight is in the range of 4500 g, the ACOG recommends consideration of primary cesarean section without labor to avoid shoulder dystocia (29). Over the longer term, GDM may be thought of as a provocative test for future diabetes. In landmark studies, O'Sullivan and Mahan found that approximately 50% of women with previous GDM had developed diabetes, primarily type 2 diabetes, within 20 years of their index pregnancy (6). Other studies have confirmed increased risk, with the magnitude varying according to the prevalence of type 2 diabetes in the population (4, 30, 31).

Medical Management


Medical management is aimed at maintaining circulating glucose concentrations in the reference interval for pregnant women. Until self-glucose monitoring became widely available in the late 1970s, women with GDM needed to travel to laboratory sites to have their blood glucose checked. This meant that the day on which glucose tests were conducted was not like an ordinary day, and the results probably did not accurately reflect what was going on in the individual's dayto-day life. As test strips and reflectance meters came on the market, it became possible to incorporate glucose testing into nearly any lifestyle.

Goals for glucose control in diabetic pregnancy were originally based on studies of healthy nondiabetic pregnant women (32). Other studies revealed lower perinatal mortality rates for diabetic pregnancies when mean glucose concentrations were kept in that reference interval (33). The ACOG recommends fasting values below 95 mg/dL (5.27 mmol/L), 1-h postprandial values below 130-140 mg/dL (7.22-7.77 mmol/L), and 2-h postprandial values below 120 mg/dL (6.66 mmol/L) (34). The ADA makes similar recommendations (1). It should be noted that these recommendations are based primarily on limited scientific evidence and expert opinion. Patients with gestational diabetes are usually advised to perform daily self-glucose monitoring after fasting and either 1h or 2h after each meal. Although many endocrinologists recommend preprandial glucose testing for nonpregnant individuals, the advantages of postprandial testing in GDM were demonstrated in a randomized trial comparing preprandial glucose testing 3 times daily with fasting and postprandial glucose measurement 3 times daily in women with GDM who required insulin (35). Postprandial testing was associated with lower rates of large-for-gestational-age offspring, fewer cesarean sections, and less neonatal hypoglycemia. It appears that the fetal pancreas is most sensitive to the height of blood glucose excursions, which typically occur after meals.


Medical nutritional therapy is the initial step in attaining euglycemia in gestational diabetes (36). Patients are counseled by a registered dietitian if one is available, or else by an individual with knowledge and expertise in the field. The diet plan is individualized according to the patient's weight and height and is based on the nutritional requirements of pregnancy as well as the principles of diet management in diabetes; success is based upon the achievement of blood glucose goals as described above. The diet is also intended to avoid ketosis and to help the mother achieve appropriate weight gain. The Institute of Medicine (IOM) recommendations for pregnancy weight gain, revised in 2009 (37), are based upon prepregnancy body mass index (BMI) (kg/[m.sup.2]). Underweight mothers (BMI <18.5) are advised to gain 28-40 pounds throughout pregnancy, and those of normal weight (BMI 18.5-24.9) should gain 25-35 pounds. Overweight women (BMI 25-29.9) should gain 15-25 pounds, and those who are obese (BMI >30) should gain 11-20 pounds. Women with GDM are advised to avoid concentrated sweets and highly processed foods because of their propensity to cause rapid rises in circulating glucose concentrations. The use of severely calorie-restricted diets for obese patients with GDM is somewhat controversial. Although some studies have demonstrated benefit in reducing macrosomia in the offspring (38), others have suggested risk of causing ketonemia and ketonuria (39) in the mothers, which may be associated with lower mental and motor function of the offspring at the ages of 3 and 7 years (40, 41). The IOM (37) does not recommend weight loss during pregnancy, even for morbidly obese women.


Oral antidiabetic agents are the second line of treatment of type 2 diabetes and are generally instituted when medical nutrition therapy has failed to provide adequate blood glucose control. There has been great interest in their use during pregnancy because insulin, the generally accepted gold standard, requires subcutaneous injections which can be uncomfortable and off-putting to patients. Two classes of oral agents have been most widely used. Sulfonylureas stimulate insulin production and release in the pancreas; they may cause hypoglycemia and are effective only when the pancreas is capable of producing insulin. Thus they are not used in women with type 1 diabetes. First-generation sulfonylureas were shown to cross the placenta and possibly cause neonatal hypoglycemia. Glyburide, a second-generation sulfonylurea, was found to be similarly effective to insulin in improving [HbA.sub.1c] concentrations, reducing macrosomia, and preventing neonatal hypoglycemia in a randomized open-label clinical trial involving women with GDM whose levels of glycemia required pharmacologic treatment (42). Results of a number of other reported studies have supported the efficacy of this drug, with additional insulin required in 6% to 25% of patients with GDM (43). Initial publications reported that glyburide did not cross the isolated, perfused placental cotyledon from the maternal to the fetal circulation (44) and was not found in cord blood (42), but subsequent investigators reported that fetal concentrations at delivery were 70% of maternal concentrations (45), although both concentrations were quite low because of the time elapsed since last dosing before delivery. Adverse fetal and neonatal effects such as neonatal hypoglycemia and macrosomia have not been reported to increase with the use of glyburide during pregnancy, but long-term studies of offspring have not been carried out. Given current concerns regarding in utero programming (46), it is important to inform patients of these remaining questions when sulfonylureas are prescribed.

The other class of drugs which have been widely used in pregnancy are the biguanides, of which metformin is the only available agent. Metformin acts as an insulin sensitizer at the liver and periphery. It does not cause hypoglycemia. A randomized trial comparing metformin to insulin in women with GDM requiring pharmacologic intervention demonstrated that the 2 approaches were similarly effective in preventing adverse pregnancy outcomes (47). As would be expected, women preferred metformin to insulin. However, nearly half of women assigned to metformin treatment required the addition of insulin to achieve adequate glycemic control. Other reported studies have had similar results (43). Metformin crosses the placenta, and fetal concentrations are considerably higher than maternal concentrations (48). Although no increase in adverse outcomes has been reported, long-term studies of the offspring have not been carried out thus far. When metformin is prescribed during pregnancy, patients should be informed that it crosses the placenta to the fetus and that potential benefits or harms are not yet known.

A number of other classes of agents are available to treat diabetes in nonpregnant individuals. Acarbose, an a-glucosidase inhibitor, prevents absorption of sugar from the gastrointestinal tract and has been investigated in at least 2 pilot studies (49, 50). Although it can decrease postprandial glucose excursions, bothersome side effects can include cramping and excessive flatus. Very little is absorbed systemically. Insulin sensitizers such as thiazolidinediones have been reported to cross the placenta and are generally not used in pregnancy.


Insulin has long been the gold standard medication when diet and exercise are not sufficient to control circulating glucose concentrations in women with GDM. Insulin derived from the pancreases of pigs and cows was initially used but elicited immune responses, with antiinsulin antibodies, in many patients. Recombinant DNA technology then enabled the production of human insulin, which was not antigenic. Various vehicles were added to delay absorption of the insulin, resulting in short-acting [e.g., regular, also known as crystalline zinc insulin (CZI)], intermediate-acting [Neutral Protamine Hagedorn (NPH)], and long-acting (ultralente) insulins. Most recently, biosynthetic insulin analogs have been developed, with single amino acid substitutions, changing the absorption characteristics. The commonly available insulins and their onset and duration of action are listed in Table 4. Insulin lispro (51) and insulin aspart (52) appear not to cross the placenta and are commonly used in pregnancy. They are rapidacting insulin analogs with a short duration of action, so they can be taken immediately before meals, providing more flexibility in meal timing than was possible with regular insulin, which needed to be taken 20-30 min before eating. NPH insulin is intermediate acting and can be mixed with short-acting insulins so as to cover the immediate meal and the subsequent meal. Longer-acting biosynthetic insulin analogs are available and are used to mimic basal insulin production. These insulin analogs appear to have no peak of action, at least in nonpregnant individuals, and last for over 24 h. Insulin detemir has been used to treat pregnant women with preexisting diabetes and was compared with NPH insulin in a randomized clinical trial (53). Insulin detemir was demonstrated to be noninferior to NPH insulin with respect to [HbA.sub.1c] concentrations at 36 weeks, and fasting glucose concentrations were lower with detemir at 24 and 36 weeks gestation. Rates of hypoglycemia were similar in both groups. As a result of this study, insulin detemir has been reclassified by the US Food and Drug Administration (FDA) to FDA Pregnancy Category B. However, data have not yet been published regarding whether insulin detemir crosses the placenta. Insulin glargine, which is FDA Pregnancy Category C, has been shown not to cross the placenta when used at therapeutic doses (54). Metaanalyses have not shown any differences in maternal or fetal outcomes with insulin glargine compared to NPH insulin (55, 56). As a general rule, patients with GDM can be safely and effectively managed with combinations of NPH and short-acting insulin analogs, without the need for long-acting analogs.

Management during Labor and the Puerperium

Diabetic management during labor and delivery is aimed at maintaining maternal euglycemia to avoid neonatal hypoglycemia. The hyperinsulinemic fetus of a diabetic mother, having been exposed to hyperglycemia throughout the pregnancy, exhibits a brisk insulin response to a glucose challenge. If maternal glucose concentrations are increased just before delivery, neonatal hypoglycemia is likely to develop as the newborn adapts to being cut off from the placental supply of glucose. Neonatal hypoglycemia can cause seizures and other problems and so should be avoided. Therefore, at our institution, point-of-care capillary glucose concentrations are checked frequently during labor, with a goal of 70-120 mg/dL (3.89-6.66 mmol/L). Although maternal glucose concentrations in the range of 60 and even 50 mg/dL are generally well tolerated, healthy newborns drop their glucose concentrations approximately in half during the first few hours of life, so it is best for maternal glucose to be no lower than 70 mg/dL at delivery. Most women with gestational diabetes will not become hyperglycemic during labor, because they are not eating (although they are generally allowed to drink fluids). We often provide an intravenous infusion of 5% dextrose to meet the caloric needs of labor. If maternal glucose concentrations exceed 120 mg/dL a constant intravenous insulin infusion can be administered starting at 1 U/h. This is virtually always needed for gravidas with type 1 diabetes, sometimes needed for those with type 2 diabetes, and rarely necessary for gestational diabetes.

Once delivery has occurred, and the fetal-placental unit is no longer releasing hormones that cause insulin resistance, maternal glucose metabolism generally rapidly returns to normal. Because some women with gestational diabetes actually had undiagnosed preexisting diabetes before their pregnancy, we measure a fasting plasma glucose on the morning after delivery to make sure that no further treatment is needed at that time.

Obstetric Management


Pregnancies complicated by gestational diabetes are at increased risk of stillbirth (2). Although there is no single best evidence-based approach to monitoring fetal well-being in gestational diabetic pregnancies, the ACOG has stated: "Despite the lack of conclusive data, it would seem reasonable that women whose GDM is not well controlled, who require insulin, or who have other risk factors such as hypertension or adverse obstetric history should be managed the same as individuals with preexisting diabetes. The particular antepartum test selected, whether nonstress test, contraction stress test, or biophysical profile, may be chosen according to local practice" (34). In our institution GDM mothers with risk factors noted above begin twice weekly nonstress tests and amniotic fluid indices at between 32 and 36 weeks, depending upon the severity of the risk factors. Those with no risk factors and whose circulating glucose concentrations are within targets, using medical nutrition therapy alone, start weekly testing at 36 weeks.


The rate of macrosomia in GDM varies, depending upon the diagnostic criteria and the method of treatment. In a randomized trial of identification and treatment of mild forms of GDM, macrosomia (birthweight >4000 g) was present in 21% (27) and 14% (28) of untreated pregnancies, which was about twice the rate in each study in pregnancies in which GDM was identified and treated. Because GDM is associated with fetal macrosomia, and macrosomia in a fetus of a diabetic mother is associated with an increased risk of shoulder dystocia compared to the risk in a similar-weight fetus of a nondiabetic mother, normalization of maternal glucose is the most important means of prevention of this problem. However, such efforts are not always successful, and large babies are sometimes born to mothers whose GDM is well controlled. Therefore periodic ultrasound imaging of the fetus is used to estimate fetal weight and growth trajectory. Caution should be exercised in interpreting ultrasound fetal weight estimations because the range of error is relatively wide. One series of investigations has demonstrated the successful use of ultrasound estimates of fetal growth trajectories to determine which GDM mothers may or may not benefit from insulin treatment with (57) or without (58) increased fasting glucose concentrations.


There is an increased risk of stillbirth in gestational diabetic pregnancies, particularly when glucose concentrations are not within target ranges and the fetus is presumably hyperinsulinemic. A 2011 workshop jointly sponsored by the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the Society for Maternal-Fetal Medicine recommended that gestational diabetic pregnancies in which glucose concentrations are well controlled, with or without medication, not be delivered electively before 39 weeks (59). When GDM is poorly controlled the timing of delivery is individualized and is generally between 34 and 39 weeks, depending upon the situation. When all of almost 200 000 pregnancies complicated by GDM in California over a 10-year period were analyzed, the stillbirth rate plus infant mortality rate associated with delivery at various gestational ages was compared to determine the risk of early delivery vs waiting 1 more week (60). Such risks were not different between 36 and 38 weeks, but at 39 weeks and beyond the relative risk of expectant management exceeded that of delivery. The absolute differences were small but significant, with the number needed to deliver at 39 weeks (vs 40 weeks) to prevent a single excess death being 1518. Because there is increased perinatal morbidity associated with early term delivery before 39 weeks (61), delivery between 39 and 40 weeks in cases of gestational diabetic pregnancy appears to be a reasonable course. At our institution we recommend induction of labor for undelivered women with well-controlled gestational diabetes at some time between 39 and 40 completed weeks of gestation, depending upon the patient's preference. Delivery is often performed earlier in patients whose GDM is not well controlled.


Gestational diabetes is not an indication for cesarean section. However, cesarean section is more common in GDM than in nondiabetic pregnancies. The absolute rates are dependent upon the criteria used for the diagnosis of GDM and the prevailing cesarean section rates in the particular location. In the randomized trials of identification and treatment of mild gestational diabetes, cesarean sections were performed in 32% of untreated vs 31% of treated (27) and 34% of untreated vs 27% of treated GDM pregnancies (28), which in the latter study was significantly higher. For example, pre-eclampsia is more likely to occur in gestational diabetic pregnancies than in nondiabetic pregnancies, and its treatment may require early delivery when the cervix is not favorable. Cesarean section may result. Macrosomia is more commonly encountered, by mechanisms outlined above, and failure to progress in labor because of disproportion between fetus and pelvis may necessitate cesarean section. Because the fetus of a diabetic mother tends to have broader shoulders compared to its head, shoulder dystocia is more likely at any given birth weight (62). A decision analysis (63) led to the conclusion that if a policy of elective cesarean section were put in place when the estimated fetal weight is [greater than or equal to] 4500 g, then 3695 cesarean sections would be needed to prevent 1 case of permanent Erb palsy in nondiabetic pregnancies, whereas 443 cesarean sections would be needed for diabetic pregnancies. The ACOG suggests offering cesarean section without labor when the estimated fetal weight in a diabetic pregnancy is [greater than or equal to] 4500 g (29). Pregnant patients with a history of infant shoulder dystocia in an earlier delivery, whose estimated fetal weight is equal to or greater than that of the previous affected offspring, are also typically offered cesareans. Another possible cause of increased cesarean sections in gestational diabetic pregnancies is the obstetrician's concern about the possibility of shoulder dystocia, even when the fetus is not large. A Canadian study (64) found that when obstetricians were blinded to the diagnosis of mild GDM and patients were not treated, cesarean sections were performed more often than in nondiabetic pregnancies and were associated with macrosomic fetuses. However, when caregivers knew the diagnosis of more severe GDM and treated it accordingly, macrosomia was reduced but cesarean sections were still performed at a greater rate than in the nondiabetic population; these cesarean sections were not confined to the macrosomic fetuses. It could be concluded that the obstetricians were more likely to intervene because of their concerns regarding macrosomia and shoulder dystocia, which were brought about by the caregivers' knowledge of the diagnosis of GDM.

Postpartum Management

Patients with gestational diabetes are prone to developing type 2 diabetes later in life. In one follow-up study (6), nearly 40% of former GDMs had been diagnosed with diabetes within 20 years of their index pregnancy. Diagnostic criteria for GDM are not too dissimilar from those for prediabetes in nonpregnant individuals (Table 3), so it is not too surprising that many women with GDM will have prediabetes after their pregnancy is completed. Some will have diabetes, and it is presumed that they had this condition before pregnancy but it was not diagnosed. In a high-risk Hispanic-American population, 9% of former GDMs had type 2 diabetes when tested at 5-8 weeks postpartum; another 10% had impaired glucose tolerance (65). A systematic review of the literature (66) revealed that the cumulative incidence of type 2 diabetes after GDM increases most rapidly during the first 5 years after delivery, and then appears to level off after 10 years. For these reasons, both the ADA (36) and ACOG (34) recommend that women with GDM undergo a 75-g, 2-h OGTT at approximately the time of their 6-week checkup. Although testing for diabetes can also be performed with a measurement of fasting plasma glucose or [HbA.sub.1c], the National Health and Nutrition Examination Survey data from 2005 to 2008 demonstrated that only 31% of adults with impaired fasting glucose [100-125 mg/dL (5.55-6.94 mmol/L)] had impaired glucose tolerance [2-h plasma glucose on a 75-g OGTT, 140 -199 mg/dL (7.77-11.05 mmol/L)] and only 58% of adults with impaired glucose tolerance had impaired fasting glucose (67). An [HbA.sub.1c] above 5.7% was present in only 32% of those with impaired fasting glucose and 32% of those with impaired glucose tolerance. A study of women with previous GDM who were tested between 6 weeks and 36 months postpartum also found that [HbA.sub.1c] was only moderately sensitive for detecting abnormal glucose tolerance (68). Former GDM mothers are presumably still in the reproductive age and the diagnosis of prediabetes or diabetes would be important information applicable to the preconception care during future pregnancies. The OGTT is the most sensitive way to diagnose prediabetes and diabetes (67, 68). The ADA recommends that women with a history of previous GDM should have lifelong screening for diabetes and prediabetes at least every 3 years (1).

Identification of patients with prediabetes allows interventions to prevent the development of type 2 diabetes. In the Diabetes Prevention Program (69), women with previous GDM and current impaired glucose tolerance, whose fasting plasma glucose was also 95-125 mg/dL (5.27-6.94 mmol/L) and who were randomized to placebo, progressed to type 2 diabetes at a rate of 15% per year. This progression rate was reduced to 7.4% per year with intensive lifestyle intervention and 7.8% per year with metformin treatment.

Public Health Implications

As the prevalence of gestational diabetes increases, it is appropriate to ask the difficult questions regarding its overall public health impact. An understanding of what resources are required for its diagnosis and treatment and how cost-effective our efforts will be is essential. An analysis of the costs and benefits of diagnosis and treatment of mild gestational diabetes [75-g, 2-h glucose tolerance test value of 140-199 mg/dL (7.7711.05 mmol/L)] revealed that the incremental direct inpatient and outpatient hospital cost of treating 1 case of mild gestational diabetes was A$539.85 (Australian dollars), and the additional charges incurred by the patient's family were A$65.21 (70). For every 100 cases of gestational diabetes that were identified and treated, 2.2 fewer babies experienced serious perinatal complications (defined as death, shoulder dystocia, bone fracture, and nerve palsy), and 1 fewer babies experienced perinatal death. The incremental cost per serious perinatal complication prevented was A$27 503. There is great concern that the new recommendations from IADPSG/ADA may increase healthcare costs without improving the health of our population (71). A Canadian randomized trial (72) revealed that the per patient direct costs of screening and testing would be greater (Can$108.38 [Canadian dollars]) with a 1-step approach using the WHO criteria (16) than with 2-step protocols utilizing either the NDDG-recommended (11) 100-g, 3-h OGTT criteria (Can$91.61) or the Canadian Diabetes Association (73) criteria (Can$89.03). In this randomized trial the investigators did not test the new IADPSG/ADA criteria (1). The prevalence of gestational diabetes was similar (3.6%-3.7%) in each of the 3 groups. Assuming that the prevalence of GDM by the new ADA criteria would be in the 16% range, the cost per case of GDM diagnosed would presumably fall from Can$3010 to Can$677, and in that sense the ADA 1-step approach would be considerably more cost-effective than either 2-step approach. A decision analysis model (74) was used to compared no screening with the current ACOG approach (13) and the IADPSG/ADA approach (1). Compared to no screening, the IADPSG/ADA strategy was equally as cost-effective as the current ACOG strategy only if treatment included postdelivery care, which reduces the incidence of subsequent diabetes. It is to be expected that more information about public health implications will become available if and when the new criteria are more widely adopted.

Regardless of the criteria used, gestational diabetes is increasing in prevalence around the world in parallel with the increasing prevalence of obesity and type 2 diabetes. All of these trends will no doubt stress the healthcare systems both in the US and abroad. Hopefully, more efficient and more scientifically based approaches to diagnosis and treatment will evolve to keep up with demands. Ultimately, prevention must be the goal.

Author Contributions: All authors confirmed they have contributed to the intellectual content of this paper and have met the following 3 requirements: (a) significant contributions to the conception and design, acquisition of data, oranalysis and interpretation of data; (b) drafting or revising the article for intellectual content; and (c) final approval of the published article.

Authors' Disclosures or Potential Conflicts of Interest: No authors declared any potential conflicts of interest.


(1.) ADA. Standards of medical care in diabetes 2013. Diabetes Care 2013; 36(Suppl 1):s11-66.

(2.) O'Sullivan JB, Gellis SS, Dandrow RV, Tenney BO. The potential diabetic and her treatment in pregnancy. Obstet Gynecol 1966; 27:683-9.

(3.) Pettitt DJ, Bennett PH, Saad MF, Charles MA, Nelson RG, Knowler WC. Abnormal glucose tolerance during pregnancy in Pima Indian women: long-term effects on offspring. Diabetes 1991; 40(Suppl 2):126-30.

(4.) Damm P. Future risk of diabetes in mother and child after gestational diabetes mellitus. Int J Gynecol Obstet 2009; 104:525-6.

(5.) Dabalkea D. The predisposition to obesity and diabetes in offspring of diabetic mothers. Diabetes Care 2007; 30(Suppl 2):S169-74.

(6.) O'Sullivan JB. Subsequent morbidity among gestational diabetic women. In: Sutherland HW and Stowers JM, eds. Carbohydrate metabolism in pregnancy and the newborn. New York: Churchill Livingstone; 1984. p 174-80.

(7.) Duncan JM. On puerperal diabetes. Trans Obstet Soc Lond 1882; 24:256-85.

(8.) Jackson WPU. Studies in pre-diabetes. Br Med J 1952; 3:690-6.

(9.) Carrington ER, Shuman CR, Reardon HS. Evaluation of the prediabetic state during pregnancy. Obstet Gynecol 1957; 9:664-9.

(10.) O'Sullivan JB, Mahan CM. Criteria for the oral glucose tolerance test in pregnancy. Diabetes 1964; 13:278-85.

(11.) NDDG. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979; 28:1039-57.

(12.) Carpenter MW, Coustan DR. Criteria for screening tests for gestational diabetes. Am J Obstet Gynecol 1982; 144:768-73.

(13.) ACOG. Committee opinion no. 504: screening and diagnosis of gestational diabetes. Obstet Gynecol 2011; 118:751-3.

(14.) Sacks DA, Abu-Fadil S, Greenspoon JS, Fotheringham N. Do the current standards for glucose tolerance testing in pregnancy represent a valid conversion of O'Sullivan's original criteria? Am J Obstet Gynecol 1989; 161:638-41.

(15.) Cutchie WA, Cheung NW, Simmons D. Comparison of international and New Zealand guidelines for the care of pregnant women with Diabetes. Diabet Med 2006; 23:460-8.

(16.) WHO. About diabetes. (Accessed January 2013).

(17.) Schneider S, Bock C, Wetzel M, Maul H, Loerbroks A. The prevalence of gestational diabetes in advanced countries. J Perinat Med 2012; 40:51120.

(18.) Bardenheier BH, Elixhauser A, Imperatore G, Dev lin HM, Kuklina EV, Geiss LS, Correa A. Variation in prevalence of gestational diabetes among hospital discharges for obstetric delivery across 23 states in the United States. Diabetes Care 2013; 36:1209-14.

(19.) HAPO Study Cooperative Research Group, Metzger BE, Lowe LP, DyerAR, Trimble ER, Chaovarindr U, et al. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med 2008; 358:19912002.

(20.) Pedersen J. The pregnant diabetic and her newborn; problems and management. Baltimore: Williams & Wilkins Co.; 1967. Chapter 9, Pathogenesis of the characteristic features of newborn infants of diabetic women; p 128-37.

(21.) International Association of Diabetes and Pregnancy Study Groups Consensus Panel, Metzger BE, Gabbe SG, Persson B, Buchanan TA, Catalano PA, et al. IADPSG recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care 2010; 33:676-81.

(22.) Coustan DR. Point: the American Diabetes Association and the International Association of Diabetes and Pregnancy study groups recommendations for diagnosing gestational diabetes should be used worldwide. Clin Chem 2012; 58:1094-7.

(23.) Blackwell SC. Counterpoint: enough evidence to treat? The American College of Obstetricians and Gynecologists guidelines. Clin Chem 2012; 58: 1098-100.

(24.) ADA. Diabetes statistics. http://www.diabetes. org/diabetes-basics/diabetes-statistics/ (Accessed January 2013).

(25.) ADA. National diabetes fact sheet, 2011. http:// (Accessed January 2013).

(26.) Galan HL, Battaglia FC. The biology of abnormal fetal growth and development. In: Reece EA, Coustan DR, Gabbe SG, eds. Diabetes in women. Philadelphia: Lippincott Williams & Wilkins; 2004. p 159-67.

(27.) Crowther CA, Hiller JE, Moss JR, McPhee AJ, Jeffries WS, Robinson JS; Australian Carbohydrate Intolerance Study in Pregnant Women (ACHOIS) Trial Group. Effect of treatment of gestational diabetes on pregnancy outcomes. N Engl J Med 2005; 352:2477-86.

(28.) Landon MB, Spong CY, Thom E, Carpenter MW, Ramin SM, Casey B, et al. A multicenter, randomized trial of treatment for mild gestational diabetes. N Engl J Med 2009; 361:1339-48.

(29.) ACOG. Fetal macrosomia. 2000. ACOG practice bulletin no. 22. Available from: William H. Barth, Jr. provided assistance. Reaffirmed 2013.

(30.) Coustan DR, Carpenter MW, O'Sullivan PS, Carr SR. Gestational diabetes: predictors of subsequent disordered glucose metabolism. Am J Obstet Gynecol 1993; 168:1139-44.

(31.) Schaefer-Graf UM, Buchanan TA, Xiang AH, Peters RK, Kjos SL. Clinical predictors for a high risk for the development of diabetes mellitus in the early puerperium in women with recent gestational diabetes. Am J Obstet Gynecol 2002; 186: 751-6.

(32.) Lewis SB, Wallin JD, Kuzuya H, Murray WK, Coustan DR, Daane TA, Rubenstein AH. Circadian variation of serum glucose, C-peptide immunoreactivity and free insulin in normal and insulin treated diabetic pregnant subjects. Diabetologia 1976; 12:343-50.

(33.) Karlsson K, Kjellmer I. The outcome of diabetic pregnancies in relation to the mother's blood glucose level. Am J Obstet Gynecol 1972; 112: 213-20.

(34.) ACOG Committee on Practice Bulletins--Obstetrics. ACOG practice bulletin. Clinical management guidelines for obstetrician-gynecologists. Number 30, September 2001 (replaces technical bulletin number 200, December 1994). Gestational diabetes. Obstet Gynecol 2001; 98:525-38. Reaffirmed 2010.

(35.) de Veciana M, Major CA, Morgan MA, Asrat T, Toohey JS, Lien JM, Evans AT. Postprandial versus preprandial blood glucose monitoring in women with gestational diabetes mellitus requiring insulin therapy. N Engl J Med 1995; 333:1237-41.

(36.) ADA. Gestational diabetes mellitus [Position statement]. Diabetes Care 2004; 27 Suppl 1:S8890.

(37.) IOM of the National Academies. Weight gain during pregnancy: reexamining the guidelines. http://iom. edu/Reports/2009/Weight-Gain-During-PregnancyReexamining-the-Guidelines.aspx (Accessed January 2013).

(38.) Dornhorst A, Nicholls JSD, Probst F, Paterson CM, Hollier KL, Elkeles RS, Beard RW. Calorie restriction for treatment of gestational diabetes. Diabetes 1991; 40 Suppl 2:161-4.

(39.) Knopp RH, Magee MS, Raisys V, Benedetti T, Bonet B. Hypocaloric diets and ketogenesis in the management of obese gestational diabetic women. J Am Coll Nutr 1991; 10:649-67.

(40.) Rizzo T, Metzger BE, Burns WJ, Burns K. Correlations between antepartum maternal metabolism and child intelligence. N Engl J Med 1991; 325:911-6.

(41.) Rizzo TA, Dooley SL, Metzger BE, Cho NH, Ogata ES, Silverman BL. Prenatal and perinatal influences on long-term psychomotor development in offspring of diabetic mothers. Am J Obstet Gynecol 1995; 173:1753-8.

(42.) Langer O, Conway DL, Berkus MD, Xenakis EM, Gonzales O. A comparison of glyburide and insulin in women with gestational diabetes mellitus. N Engl J Med 2000; 343:1134-8.

(43.) Nicholson W, Baptiste-Roberts K. Oral hypoglycaemic agents during pregnancy: the evidence for effectiveness and safety. Best Pract Res Clin Obstet Gynaecol 2011; 25:51-63.

(44.) Elliott BD, Langer O, Schenker S, Johnson RF. Insignificant transfer of glyburide occurs across the human placenta. Am J Obstet Gynecol 1991; 165:807-12.

(45.) Hebert MF, Ma X, Naraharisetti SB, Krudys KM, Umans JG, Hankins GD, et al. Are we optimizing gestational diabetes treatment with glyburide? The pharmacologic basis for better clinical practice. Clin Pharmacol Ther 2009; 85:607-14.

(46.) Lau C, Roger JM, Desai M, Ross MG. Fetal programming of adult disease: implications for prenatal care. Obstet Gynecol 2011; 117:978-85.

(47.) Rowan, JA, Hague WM, Gao W, Battin MR, Moore MP; MiG Trial Investigators. Metformin versus insulin for the treatment of gestational diabetes. N Engl J Med 2008; 358:2003-15.

(48.) Vanky E, Zahlsen K, Spigset O, Carlsen SM. Placental passage of metformin in women with polycystic ovary syndrome. Fertil Steril 2005; 83: 1575-8.

(49.) Zarate A, Ochoa R, Hernandez M, Basurto L. Effectiveness of acarbose in the control of glucose tolerance worsening in pregnancy. Ginecol Obstet Mex 2000; 68:42-5.

(50.) deVeciana M, Trail PA, Lau TK, Dulaney K. A comparison of oral acarbose and insulin in women with gestational diabetes mellitus. Obstet Gynecol 2002; 99 Suppl:5S.

(51.) Jovanovic L, Ilic S, Pettitt DJ, Hugo K, Gutierrez M, Bowsher RR, Bastyr EJ 3rd. The metabolic and immunologic effects of insulin lispro in gestational diabetes. Diabetes Care 1999; 22:1422-6.

(52.) McCance DR, Damm P, Mathiesen ER, Hod M, Kaaja R, Dunne F, et al. Evaluation of insulin antibodies and placental transfer of insulin aspart in pregnant women with type 1 diabetes mellitus. Diabetologia 2008; 51:2141-3.

(53.) Mathiesen ER, Hod M, Ivanisevic M, Garcia SD, Brondsted L, Jovanovic L, et al. Maternal efficacy and safety outcomes in a randomized, controlled trial comparing insulin detemir with NPH insulin in 310 pregnant women with type 1 diabetes. Diabetes Care 2012; 35:2012-7.

(54.) Pollex EK, Feig DS, Lubetsky A, Yip PM, Koren G. Insulin glargine safety in pregnancy: a transplacental transfer study. Diabetes Care 2010; 33:29-33.

(55.) Lepercq J, Lin J, Hall GC, Wang E, Dain MP, Riddle MC, Home PD. Meta-analysis of maternal and neonatal outcomes associated with the use of insulin glargine versus NPH insulin during pregnancy. Obstet Gynecol Int 2012; :649070.

(56.) Pollex E, Moretti ME, Koren G, Feig D. Safety of insulin glargine use in pregnancy: a systematic review and meta-analysis. Ann Pharmacother 2011; 45:9-16.

(57.) Kjos SL, Schaefer-Graf U, Sardesi S, Peters RK, Buley A, Xiang AH, et al. A randomized controlled trial using glycemic plus fetal ultrasound parameters versus glycemic parameters to determine insulin therapy in gestational diabetes with fasting hyperglycemia. Diabetes Care 2001; 24:190410.

(58.) Buchanan TA, Kjos SL, Montoro MN, Wu PY, Madrilejo NG, Gonzalez M, et al. Use of fetal ultrasound to select metabolic therapy for pregnancies complicated by mild gestational diabetes. Diabetes Care 1994; 17:275-83.

(59.) Spong CY, Mercer BM, D'Alton M, Kilpatrick S, Blackwell S, Saade G. Timing of indicated latepreterm and early-term birth. Obstet Gynecol 2011; 118:323-33.

(60.) Rosenstein MG, Cheng YW, Snowden JM, Nicholson JM, Doss AE, Caughey AB. The risk of stillbirth and infant death stratified by gestational age in women with gestational diabetes. Am J Obstet Gynecol 2012; 206:309.e1-7.

(61.) Tita AT, Landon MB, Spong CY, Lai Y, Leveno KJ, Varner MW, et al. Timing of elective repeat cesarean delivery at term and neonatal outcomes. N Engl J Med 2009; 360:111-20.

(62.) Acker DB, Sachs BP, Friedman EA. Risk factors for shoulder dystocia. Obstet Gynecol 1985; 66: 762-8.

(63.) Rouse DJ, Owen J, Goldenberg RL, Cliver SP. The effectiveness and costs of elective cesarean delivery for fetal macrosomia diagnosed by ultrasound. JAMA 1996; 276:1480-6.

(64.) Naylor CD, Sermer M, Chen E, Sykora K. Cesarean delivery in relation to birth weight and gesta tional glucose tolerance: pathophysiology or practice style? Toronto Trihospital Gestational Diabetes Investigators. JAMA 1996; 275:1165-70.

(65.) Kjos SL, Buchanan TA, Greenspoon JS, Montoro M, Bernstein GS, Mestman JH. Gestational diabetes mellitus: the prevalence of glucose intolerance and diabetes mellitus in the first two months post partum. Am J Obstet Gynecol 1990; 163:93-8.

(66.) Kim C, Newton KM, Knopp RH. Gestational diabetes and the incidence of type 2 diabetes. Diabetes Care 2002; 25:1862-8.

(67.) James C, Bullard KM, Rolka DB, Geiss LS, Williams DE, Cowie CC et al. Implications of alternative definitions of prediabetes for prevalence in US adults. Diabetes Care 2011; 34:387-91.

(68.) Kim C, Herman WH, Cheung NW, Gunderson EP, Richardson C. Comparison of hemoglobin A1c

with fasting plasma glucose and 2-h postchallenge glucose for risk stratification among women with recent gestational diabetes mellitus. Diabetes Care 2011; 34:1949-51.

(69.) Ratner RE, Christophi CA, Metzger BE, Dabelea D, Bennett PH, Pi-Sunyer X, et al. Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions. J Clin Endo Metab 2008; 93: 4774-9.

(70.) Moss JR, Crowther CA, Hiller JE, Willson KJ, Roninson JS; Aiustralian Carbohydrate Intolerance Study in Pregnant Women Group. Costs and consequences of treatment for mild gestational diabetes mellitus: evaluation from the ACHOIS randomized trial. BMC Pregnancy Childbirth 2007; 7:27.

(71.) Langer O, Umans JG, Miodovnik M. Perspectives on the proposed gestational diabetes mellitus

diagnostic criteria. Obstet Gynecol 2013; 121: 177-82.

(72.) Meltzer SJ, Snyder J, Penrod JR, Nudi M, Norin L. Gestational diabetes mellitus screening and diagnosis: a prospective randomised controlled trial comparing costs of one-step and two-step methods. BJOG 2010; 117:407-15.

(73.) Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008; 32:S1-201.

(74.) Werner EF, Pettker CM, Zuckerwise L, Reel M, Funai EF, Henderson J, Thung SF. Screening for gestational diabetes mellitus: are the criteria proposed by the International Association of the Diabetes and Pregnancy Study Groups costeffective? Diabetes Care 2012; 35:529-35.

Donald R. Coustan [1,2] *

[1] Department of Obstetrics and Gynecology, Warren Alpert Medical School of Brown University and 1 2 Division of Maternal-Fetal Medicine, Women & Infants Hospital of Rhode Island, Providence, RI.

* Address correspondence to this author at: Warren Alpert Medical School of Brown University, 101 Dudley St., Providence, RI 02905. Fax 401-543-7622;


Received January 14, 2013; accepted March 7, 2013.

Previously published online at DOI: 10.1373/clinchem.2013.203331

[3] Nonstandard abbreviations: GDM, gestational diabetes mellitus; OGTT, oral glucose tolerance test; NDDG, National Diabetes Data Group; C&C, Carpenter and Coustan; ACOG, American College of Obstetricians and Gynecologists; ADA, American Diabetes Association; HAPO, Hyperglycemia and Adverse Pregnancy Outcome study; NICU, neonatal intensive care unit; IADPSG, International Association of Diabetes In Pregnancy Study Groups; [HbA.sub.1c], hemoglobin [A.sub.1c]; IOM, Institute of Medicine; BMI, body mass index; CZI, crystalline zinc insulin; NPH, Neutral Protamine Hagedorn; FDA, US Food and Drug Administration.
Table 1. O'Sullivan criteria for diagnosing gestational
diabetes by using the 100-g, 3-h OGTT, along with

subsequently derived values.

                  Threshold glucose values,
                  mg/dL (mmol/L)

Time of glucose   Original values          Rounded O'Sullivan
measurement       [O'Sullivan and Mahan    values
                  (10)], venous whole
                  blood, Somogyi-Nelson

Fasting           90 (5.00)                90 (5.00)

1 h               165 (9.16)               165(9.16)
2 h               143 (7.94)               145 (8.05)
3 h               127 (7.05)               125 (6.94)

                  Threshold glucose values,
                  mg/dL (mmol/L)

Time of glucose   NDDG modification     C&C modification
measurement       [NDDG (11)], plasma   [Carpenter and Coustan
                                        (12)], plasma, glucose

Fasting           105 (5.83)            95 (5.27)

1 h               190 (10.55)           180(9.99)
2 h               165(9.16)             155 (8.60)
3 h               145 (8.05)            140 (7.77)

Table 2. IADPSG Recommendations. (a)

At first visit, assign diagnosis of preexisting diabetes if any of
the following are present:

Fasting plasma glucose [greater than or equal to] 126 mg/dL
  ([greater than or equal to] 6.99 mmol/L)

[HbA.sub.1c] >6.5% ([greater than or equal to] 8 mmol/mol)

Random plasma glucose [greater than or equal to] 200 mg/dL
  ([greater than or equal to] 11.1 mmol/L)
  (confirmed by FPG or [HbA.sub.1c])

At first visit, assign diagnosis of gestational
  diabetes if present:

Fasting plasma glucose [greater than or equal to] 92 mg/dL
  ([greater than or equal to] 5.11 mmol/L) and
  <126 mg/dL (<6.99 mmol/L)

At 24-28 weeks gestation, perform 75-g, 2-h OGTT. Assign
diagnosis of gestational diabetes if one or more of the
following plasma glucose values is met or exceeded:

Fasting 92 mg/dL (5.11 mmol/L)

1 h 180 mg/dL (9.99 mmol/L)

2 h 153 mg/dL (8.49 mmol/L)

(a) Adapted from the International Association
of Diabetes and Pregnancy Study Groups Consensus
Panel (21).

Table 3. Diagnostic criteria for diabetes and
prediabetes in nonpregnant individuals.3

                   Fasting plasma glucose

Diabetes           [greater than or
                     equal to] 126 mg/dL (b)
                   [greater than or
                     equal to] 6.99 mmol/L

Impaired fasting   100-125 mg/dL
  glucose          5.55-6.94 mmol/L
Impaired glucose   --

                   2-h plasma glucose
                   on 75-g, 2-h OGTT

Diabetes           [greater than or
                     equal to] 200 mg/dL (b)
                   [greater than or
                     equal to] 11.1 mmol/L

Impaired fasting   --
Impaired glucose   140-199 mg/dL
  tolerance        7.77-11.05 mmol/L

                   Hb [A.sub.1c]

Diabetes           [greater than or
                     equal to] 6.5% (b)
                   [greater than or
                     equal to] 48 mmol/mol

Prediabetes        5.7%-6.4%
Impaired fasting
Impaired glucose

                   Random plasma

Diabetes           [greater than or
                     equal to] 200 mg/dL (c)
                   [greater than or
                     equal to] 11.1 mmol/L

Impaired fasting
Impaired glucose

(a) Adapted from ADA (1)

(b) In the absence of unequivocal hyperglycemia, results
should be confirmed by repeat testing.

(c) In a patient with classic symptoms
of hyperglycemia or hyperglycemic crisis.

Table 4. Characteristics of various insulin preparations
(based on package inserts).

                              Onset, h     Peak, h      Duration, h

Rapid-acting analogs
  Insulin lispro (Humalog)    <0.25-0.5    0.5-2.5          3-5
  Insulin aspart (Novolog)      <0.25        1-3            3-5
  Insulin glulisine (Apidra)    <0.25       0.75-2          3-5
  Regular insulin, CZI,         0.5-1        2-3            5-8
  NPH, isophane                  2-4         4-10          10-16
Long-acting analogs
  Insulin glargine (Lantus)       2       Relatively       11-24
  Insulin detemir (Levemir)      1-2      Relatively   Dose dependent
                                              flat        12 h for
                                                           0.2 U/kg
                                                          14 h for
                                                           0.4 U/kg
                                                       range 7.6-24 h
COPYRIGHT 2013 American Association for Clinical Chemistry, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2013 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Coustan, Donald R.
Publication:Clinical Chemistry
Article Type:Report
Date:Sep 1, 2013
Previous Article:A 4-year-old girl with gastroenteritis, anemia, thrombocytopenia, and hematuria.
Next Article:The importance of commutability of reference materials used as calibrators: the example of ceruloplasmin.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters